Brooklyn ImmunoTherapeutics Inc. (AMEX: BTX) started the day on May 03, 2021, with a price increase of 57.63% at $78.50. During the day, the stock rose to $80.67 and sunk to $57.63 before settling in for the price of $49.80 at the close. Taking a more long-term approach, BTX posted a 52-week range of $1.88-$59.59.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -25.00%. Meanwhile, its Annual Earning per share during the time was 17.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -110.90%. This publicly-traded company’s shares outstanding now amounts to $1.48 million. The organization now has a market capitalization sitting at $2.24 billion.
Let’s gauge the efficiency of the firm, which has a total of 22 employees. It has generated 263,636 per worker during the last fiscal year. Meanwhile, its income per employee was -200,682. The stock had 8.85 Receivables turnover and 0.60 Total Asset turnover. For the Profitability, stocks gross margin was +46.41, operating margin was -93.09 and Pretax Margin of -76.22.
Brooklyn ImmunoTherapeutics Inc. (BTX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Brooklyn ImmunoTherapeutics Inc.’s current insider ownership accounts for 8.10%, in contrast to 0.20% institutional ownership.
Brooklyn ImmunoTherapeutics Inc. (BTX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2019, the organization reported -$0.2 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.05) by -$0.15. This company achieved a net margin of -76.12 while generating a return on equity of -148.60. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Brooklyn ImmunoTherapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -110.90%.
Brooklyn ImmunoTherapeutics Inc. (AMEX: BTX) Trading Performance Indicators
Let’s observe the current performance indicators for Brooklyn ImmunoTherapeutics Inc. (BTX). It’s Quick Ratio in the last reported quarter now stands at 0.70. The Stock has managed to achieve an average true range (ATR) of 8.91. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 386.14.
In the same vein, BTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.04.
Technical Analysis of Brooklyn ImmunoTherapeutics Inc. (BTX)
If we take a close look at the recent performances of Brooklyn ImmunoTherapeutics Inc. (AMEX: BTX), its last 5-days Average volume was 34.88 million that shows progress from its year to date volume of 11.45 million. During the previous 9 days, stock’s Stochastic %D was recorded 78.53% While, its Average True Range was 12.27.